News and Events
Stay up to date with our latest news, milestones, and industry events shaping our work across drug discovery and development.
Targeted Protein Degradation: From Ubiquitin to your Toolbox for VAV1 Degraders
Precedo Inc. provides in vitro biological evaluation of VAV1 degraders and in vivo assessment using autoimmune disease models, combined with DMPK studies to comprehensively evaluate their degradation properties and ADME characteristics.
In April 2024, PRECEDO attended the 25th International Society for Biological and Environmental Repositories (ISBER) Annual Meeting in Melbourne, Australia. Together with biobankers from over 30 countries, we engaged in discussions on the future direction of biobanking for the next 25 years. Among the key emerging trends, “Service Biobank” was identified as a major direction, and our Living Cancer Primary Cell Biobank and its translational platforms received strong recognition from attending experts.
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn